DNA synthesis (cytarabine, antimetabolite) / Topoisomerase II

Class

Liposomal fixed-ratio combination chemotherapy (CombiPlex platform: cytarabine + daunorubicin co-encapsulated at a synergistic 5:1 molar ratio)

Pathway

DNA synthesis inhibition and DNA damage via topoisomerase II poisoning; preferential uptake into leukemic blasts

Notes

original target text: DNA synthesis (cytarabine, antimetabolite) / Topoisomerase II (daunorubicin, anthracycline)

Cytarabine and daunorubicin are two chemotherapy agents that damage cancer cells through different mechanisms, and their combination has long been a backbone of treatment for acute myeloid leukemia. Cytarabine is an antimetabolite: a modified nucleoside that becomes incorporated into replicating DNA, stalling the copying machinery and triggering cell death in dividing cells. Daunorubicin is an anthracycline that poisons topoisomerase II, an enzyme that normally relieves torsional strain in DNA by making transient double-strand breaks and resealing them; the drug traps the enzyme mid-cycle, leaving persistent breaks that overwhelm repair capacity. Because leukemic blasts divide rapidly, they are especially vulnerable to both insults. Laboratory work found that the proportion in which these two drugs reach a cell shapes whether they act synergistically or antagonistically, motivating formulations that co-encapsulate them in a liposome, a lipid vesicle, at a fixed molar ratio designed to preserve that favorable proportion during circulation and delivery, along with preferential accumulation in leukemic cells over normal marrow. This dual-target, fixed-ratio approach is relevant wherever combination cytotoxic chemotherapy for aggressive leukemias is used.